These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
    Author: Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P, Neo-I-30 Study Group.
    Journal: J Am Acad Dermatol; 2006 Oct; 55(4):705-9. PubMed ID: 17010756.
    Abstract:
    BACKGROUND: Treatment of severe recalcitrant chronic idiopathic urticaria (CIU) is difficult. OBJECTIVE: To assess the efficacy and safety of oral cyclosporin A (CsA) in CIU. METHODS: The response to CsA was evaluated in 99 CIU patients with a double-blind, randomized, three-armed study: 16-week CsA, 8-week CsA +8-week placebo, and 16-week placebo. All patients received cetirizine throughout the study period and were followed-up after 8 weeks. RESULTS: Fewer therapeutic failures occurred with 16-week CsA (n = 3) than with placebo (n = 11) and 8-week CsA (n = 8). After 8 and 16 weeks, symptom scores significantly improved in both CsA groups over with placebo. Two patients discontinued because of hypertension. LIMITATIONS: During the study period, CsA was not administered at a constant dose; from day 28 the daily dose was 3 mg/kg, which is likely to be less effective and better tolerated than higher dosages. CONCLUSION: CsA in addition to background therapy with cetirizine may be useful in the treatment of CIU.
    [Abstract] [Full Text] [Related] [New Search]